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Background: The present study aimed to elucidate the clinicopathologic role of insulin-like growth factor-1
receptor (IGF1R) and IGF binding protein-3 (IGFBP3) in patients with pancreatic cancer. The function of IGFBP3 is
controversial, because both inhibition and facilitation of the action of IGF as well as IGF-independent effects have
been reported. In this study, IGF1R and IGFBP3 expression was examined, and their potential roles as prognostic
markers in patients with pancreatic cancer were evaluated.
Methods: Clinicopathological features of 122 patients with curatively resected pancreatic cancer were
retrospectively reviewed, and expression of IGF1R and IGFBP3 was immunohistochemically analyzed.
Results: Expression of IGF1R and IGFBP3 was observed in 50 (41.0%) and 37 (30.3%) patients, respectively. IGF1R
expression was significantly associated with histological grade (p = 0.037). IGFBP3 expression had a significant
association with tumor location (p = 0.023), and a significant inverse association with venous invasion (p = 0.037).
Tumors with IGF1R-positive and IGFBP3-negative expression (n = 32) were significantly frequently Stage II and III
(p = 0.011). The prognosis for IGF1R positive patients was significantly poorer than that for IGF1R negative
patients (p = 0.0181). IGFBP3 protein expression did not correlate significantly with patient survival. The subset of
patients with both positive IGF1R and negative IGFBP3 had worse overall survival (8.8 months versus 12.6
months, respectively, p < 0.001).
Conclusion: IGF1R signaling might be associated with tumor aggressiveness, and IGFBP3 might show
antiproliferative effects in pancreatic cancer. Both high IGF1R expression and low IGFBP3 expression represent
useful prognostic markers for patients with curatively resected pancreatic cancer.
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Pancreatic ductal adenocarcinoma (PDAC) is one of the
most lethal solid tumors, and carries an extremely poor
prognosis [1]. Although the management and treatment
of patients with pancreatic cancer have improved over
the last few decades, the overall 5-year survival rate
remains less than 5% [2]. Long-term survival is rare,
even in patients who undergo a histologically curative* Correspondence: m9312510@med.osaka-cu.ac.jp
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reproduction in any medium, provided the oroperation, with overall 5-year survival rates ranging
from 10% to 25% [3,4]. The high mortality rate associated
with pancreatic cancer is known to be due to extensive
invasion into surrounding tissues and metastasis to distant
organs at the time of diagnosis (or even after a curative
operation); however, the molecular mechanisms of the
highly aggressive nature of PDAC remains unclear [5].
Previous studies have shown an association between
progression of PDAC and overexpression of several
growth factors (and their receptors) including insulin-
like growth factor (IGF), vascular endothelial growth
factor (VEGF), fibroblast growth factor (FGF), and
platelet-derived growth factor (PDGF) [6-8]. Most ofal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Patients’ clinicopathological characteristics
















Medullary type (med) 1
Intermediate type (int) 85














TNM classification is according to the International Union against Cancer
(UICC, 2003).
Medullary type (med): scanty stroma, Intermediate type (int): the quantity of
stroma is intermediate between the two above types, Scirrhous type (sci):
abundant stroma.
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the IGF-I receptor (IGF1R). Binding of the ligand to
IGF1R leads to tyrosine phosphorylation of the major
receptor substrate followed by activation of certain
downstream signaling cascades [9]. The IGFs have been
implicated through IGF1R in the pathogenesis, cell prolif-
eration, and cell survival of many cancers [10,11]. IGF-1,
which is produced primarily by the liver, is known to play
an important role in the regulation of cell proliferation,
differentiation, and apoptosis [10-12]. Clinical studies in
colorectal, esophageal, and pancreatic cancers have shown
that IGF1R signaling correlates with increased tumor
growth and malignancy in vitro [8,13,14].
The IGF system is a complex network of growth factors
(IGF-I and IGF-II), cell surface trans-membrane receptors
(IGF1R), and high affinity IGF-binding proteins (IGFBPs)
that play an important role in normal cellular growth and
development, and disruption of the balance of this system
has been implicated in the etiology and progression of
breast and other cancers [15]. Activation of the IGF sys-
tem stimulates proliferation, differentiation, angiogenesis,
metastasis, survival, and resistance to anticancer therapies
in many cancers [16], supporting the idea that the IGF
system is an attractive therapeutic target. The biological
actions of IGFs are modulated by a family of IGFBPs in
the local tissue microenvironment [17,18]. IGFBP3 is part
of the family of six IGFBPs that bind the peptide growth
factors IGF-I and IGF-II with high affinity and regulate
their bioactivity [19]. IGFBP3 is the most abundant IGFBP,
being present in almost all tissues. IGFBP3 inhibits IGF1R
mediated signaling by preventing the interaction of IGFs
with IGF1R. IGFBP3 regulates the mitogenic action of
IGFs or inhibits their antiapoptotic effects through IGF-
dependent and IGF-independent mechanisms [20,21].
However, there are few evidences of an association be-
tween IGFBP3 and enhanced cell proliferation. These find-
ings have encouraged investigators to investigate whether
IGFBP3 plays a positive or negative role in IGF-promoted
tumor development.
Although serum levels of IGF-I are generally considered
to be a positive risk factor for development of colorectal
cancer, the role of IGFBP3 appears less clear. Both the
inhibition and activation of cellular functions by these
proteins have been demonstrated to depend on cell type
[22]. The present study examined IGF1R and cell




A total of 122 patients who had undergone resection of a
primary pancreatic tumor at the Department of Surgical
Oncology, Osaka City University Hospital were included.
The pathologic diagnoses and classifications were madeaccording to the UICC Classification of Malignant
Tumors [23]. No patients had hematogenous metastases
or peritoneal dissemination before surgery. Histological
findings are according to the classification of pancreatic
carcinoma in Japan Pancreas Society [24]. Patients’ charac-
teristics are shown in Table 1. The median age of patients
was 68 years (range 33–84 years). A total of 79 patients
(64.8%) died during the follow-up period, and the majority
of patients were male (67.2%), and Stage II (78.7%). The
observation period is overall survival time that was set in
days as the period from the time of resection until the
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guidelines of the Declaration of Helsinki (1975). This
study was approved by the Osaka City University ethics
committee. Informed consent was obtained from all
patients prior to entry.
Immunohistochemical techniques
Sections of paraffin-embedded tissue (4-μm thick) were
prepared. Immunohistochemical staining for IGF1R and
IGFBP3 was performed using the avidin-biotin-peroxidase
complex method. In brief, the deparaffinized and hydrated
tissues were heated for 10 min at 105°C in Target Retrieval
Solution (Dako, Carpinteria, CA, USA). Then, the slides
were allowed to cool for 20 min on a lab bench in the
Target Retrieval Solution at 25°C. The slides were incu-
bated overnight at 4°C with 5 μg/mL of antihuman IGF1R
mouse monoclonal antibody (Abcam, Cambridge, MA,
USA) and 5 μg/mL of antihuman IGFBP3 rabbit poly-
clonal antibody (Abcam, Cambridge, MA, USA).
Immunohistochemical determination
All slides were examined by two of the authors who were
blinded to clinical data. The final evaluation of ambiguous
cases was decided after discussion between the two
authors. For determination of IGF1Rand IGFBP3 protein
immunoreactivity, the cytoplasm and membrane staining
intensity and patterns were evaluated according to the fol-
lowing scale. Immunoreactivity for IGF1R was evaluated
in the neoplastic epithelial cells using a combined scoring
system based on the sum of the staining intensity and the
percentage of positive cells. Scores from 0–3 were given
for the staining intensity and the percentage of positive






Figure 1 IGF1R and IGFBP3 expression in pancreatic cancer. A, Repres
staining intensity. (Original magnification X 200). IGF1R was mainly expresse
in the cell membrane and the cytoplasm of pancreatic cancer cells.observed in less than 10% of the tumor cells; score of 1+,
weak staining is detected in 10% or more of the tumor
cells; score of 2+, moderate staining is observed in 10% or
more of the tumor cells; and score of 3+, strong staining
is observed in 10% or more of the tumor cells. Scores of
0 and 1+ were considered to be negative for IGF1R
overexpression, while scores of 2+ and 3+ were consid-
ered to be positive for IGF1R overexpression. Immuno-
reactivity for IGFBP3 was evaluated in the neoplastic
epithelial cells using a combined scoring system based
on the sum of the staining intensity and the percentage
of positive cells. For determination of IGFBP3 protein
immunoreactivity, staining of antibody was considered
positive if >10% of tumor cells were stained.
Statistical analysis
The χ2-test or Fisher’s exact test was used to determine
the significance of the differences between the covariates.
Survival durations were calculated using the Kaplan-Meier
method and were analyzed by the log-rank test to com-
pare the cumulative survival durations in the patient
groups. The Cox proportional hazards model was used for
the univariate and multivariate analyses. All analyses were
performed using SPSS software (SPSS Japan, Tokyo,
Japan). A P-value < 0.05 was considered to represent stat-
istical significance.
Results
Expression of IGF1R and IGFBP3
Tumors with positive IGF1R protein showed cytoplasmic
staining. Typical images of positive immunostaining for
IGF1R in cancer cells are shown in Figure 1A. Overall,




entative IGF1R staining quantified with scores of 0 to 3+ according to
d in the cytoplasm of pancreatic cancer cells. B, IGFBP3 was expressed
Table 2 Association between IGF1R & IFGBP3 expression and clinicopathological factors in resectable pancreatic cancer
IGF1R expression IGFBP3 expression Both IGF1R (+) and IGFBP3 (−)
Characteristics positive negative positive negative positive others
n = 50 n = 72 p-value n = 37 n = 85 p-value n = 32 n = 90 p-value
Age
<60 7 18 10 15 3 22
≧60 43 54 0.139 27 70 0.238 29 68 0.07
Gender
Male 25 31 15 41 16 40
Female 25 41 0.449 22 44 0.433 16 50 0.588
T category
T1, T2 9 17 7 19 3 23
T3, T4 41 55 0.457 30 66 0.670 29 67
N category 0.077
N0 23 33 20 36 14 42
N1 27 39 0.986 17 49 0.233 18 48 0.776
Stage
I 4 11 5 10 0 15
II & III 46 61 32 75 32 75
Tumor location 0.273 0.787 0.011
proximal 31 50 30 51 18 63
distal 19 22 7 34 14 27
Tumor differentiation 0.392 0.023 0.157
Grade1, 2 46 56 34 68 28 74
Grade 3, 4 4 16 0.037 3 17 0.082 4 16 0.588
Lymphatic invasion
negative 24 42 19 47 15 51
positive 26 30 0.260 18 38 0.688 17 39 0.340
Arterial invasion
negative 43 67 33 77 27 83
positive 7 5 0.198 4 8 0.754 5 7 0.200
Venous invasion
negative 45 62 36 71 28 79
positive 5 10 0.52 1 14 0.037 4 11 0.967
Intrapancreatic nerve invasion
negative 21 38 16 43 16 43
positive 29 34 0.241 21 42 0.456 16 47 0.829
Tumor stromal volume
med & int 31 55 27 59 19 67
sci 19 17 0.087 10 26 0.692 13 23 0.108
IGFBP3 expression
negative 32 53
positive 18 19 0.256
Medullary type (med): scanty stroma, Intermediate type (int): the quantity of stroma is intermediate between the two above types, Scirrhous type (sci): abundant
stroma.
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http://www.biomedcentral.com/1471-2407/13/39223 cases had a score of 2+, and 27 cases had a score of
3+. Thus, 50 cases (41%) were positive for IGF1R
overexpression. Most of the positive staining was observed
in the cytoplasm, while two cases showed positive staining
in both membranes and cytoplasm. In contrast, no or
weak staining was seen in the cytoplasm of pancreatic
duct cells and acinar cells, and there was no staining in
the membranes. Figure 1B shows a representative picture
of IGFBP3 staining. IGFBP3 was mainly expressed in the
cytoplasm of cancer cells. Eighty-five cases of PDAC
showed negative IGFBP3 expression, whereas 37 cases
were positive.
Clinicopathological association of IGF1R and IGFBP3
expression
Table 2 shows the association of clinicopathological
characteristics and IGF1R or/and IGFBP3 expression.
IGF1R expression had a significant association with
histological grade (Fisher’s exact test, p = 0.037). Stro-
mal volume tended to be more abundant in PDAC with
IGF1R overexpression, but no significant difference
was observed (χ2 test, p = 0.087). IGFBP3 expression











































































Figure 2 Overall survival of patients based on IGF1R and IGFBP3 expr
curves in relation to the IGF1R and IGFBP3 levels in patients with pancreati
between patients with IGF1R-positive and IGF1R-negative tumors (p = 0.018
patients showed a significant correlation with overall survival (p < 0.001). IG
(p = 0.079). The co-expression of IGF1R-negative and IGFBP3-positive PDACp = 0.023), and a significant inverse association with
venous invasion (Fisher’s exact test, p = 0.037). IGFBP3
expression tended to be frequent in differentiated PDAC
in histological grade, but no significant difference was
observed (χ2 test, p = 0.082).Relationship between clinicopathological features and
tumors with IGF1R-positive and IGFBP3-negative
expression
Among the 50 patients with positive IGF1R expression,
32 patients (64.0%) had negative IGFBP3 expression.
Tumors with IGF1R-positive and IGFBP3-negative ex-
pression (n = 32) were significantly frequently found to
have Stage II and III cancer (χ2 test, p = 0.011) compared
to the other groups (n = 90). Tumors with IGF1R-positive
and IGFBP3-negative expression tended to be in older
patients (Fisher’s exact test, p = 0.07) and advanced T stage
(χ2 test, 0.077). Among the 72 patients with negative
IGF1R, 53 patients (73.6%) showed negative IGFBP3 ex-
pression, whereas 19 patients (26.4%) had positive IGFBP3


































ession. The survival curve shows the Kaplan-Meier overall survival
c cancer. A statistically significant difference in survival was observed
). The prognosis of patients with IGF1R-positive and IGFBP3-negative
FBP3 expression alone tended to be associated with overall survival
was not associated with overall survival (p = 0.218).
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Kaplan-Meier survival analyses showed a significantly
poorer overall survival in the IGF1R-positive group
compared to the IGF1R-negative group (p = 0.018).
Moreover, the prognosis of patients with IGF1R-positive
and IGFBP3-negative PDAC was significantly poorer
than that of other patients (p < 0.001). In contrast, the
prognosis of patients with IGF1R-negative and IGFBP3-
positive PDAC was not significantly correlation with
overall survival (p = 0.218), while IGFBP3 expression alone
tended to be associated with overall survival (p = 0.079)
(Figure 2). Figure 3 shows the overall survival stratified for
IGF1R and IGFBP3 expression in cancer cells according to
clinical stage II status. The prognosis for IGF1R positive
patients with stage II tumors was significantly (p = 0.0080)
poorer than that for IGF1R negative patients, while no
significant difference in the prognosis was found between
the IGF1R expression in either stage I or III tumors
(data not shown). On univariate analysis, three factors,
IGF1R overexpression, IGF1R-positive and IGFBP3-
negative expression, and lymph node metastasis, were
significantly associated with worse overall survival.
Because IGF1R status is deeply associated with IGF1R























































Figure 3 Overall survival stratified by IGF1R and IGFBP3 expression in c
IGF1R-positive cancer was significantly poorer (p = 0.008) than that of IGF1R-n
with IGF1R-positive and IGFBP3-negative tumors shows a significant correlatiowith two factors: IGF1R-positive and IGFBP3-negative
expression, and lymph node metastasis. The multivari-
ate survival analysis indicated that IGF1R-positive and
IGFBP3-negative expression, along with lymph node
metastasis, were independent prognostic indicators
(Table 3). IGF1R-positive and IGFBP3-negative expres-
sion and lymph node metastasis were independent pre-
dictors of poor prognosis.
Discussion
The present study analyzed the immunohistochemical
expression of IGF1R and IGFBP3 with clinicopathological
variables and the correlation with overall survival in 122
patients with PDAC. IGF1R expression had a significant
association with histological grade of tumor differenti-
ation, and also tended to be associated with abundant
stroma. These findings suggest that the IGF1R signaling
system might be correlated with histopathologic features
of PDAC. It has been reported that IGF1 is produced from
stromal cells [11]. There might be an interaction between
cancer cells and stromal cells via IGF/IGF1R signaling.
PDAC patients with IGF1R-positive expression showed
significantly poorer survival, compared to the IGF1R-





















































ancer cells in patients with clinical stage II tumors. Prognosis of
egative cancer in the stage II group. Analysis of prognosis of patients
n with overall survival (p = 0.0009) in patients with stage II tumors.
Table 3 Univariate and multivariate survival analyses in pancreatic cancer
Variable Univariate analysis Multivariate analysis
Hazard ratio 95% CI p-value Hazard ratio 95% CI p-value
IGF1R expression
Positive vs negative 1.714 1.091-2.693 0.020
IGFBP3 low expression
Positive vs negative 1.561 0.946-2.576 0.081
IGF1R (+) & IGFBP3 (−)
Positive vs negative 3.101 1.843-5.218 < 0.001 3.060 1.823-5.138 < 0.001
Gender
male vs female 0.975 0.623-1.525 0.911
Age
≧ 60 vs <60 1.444 0.822-2.537 0.201
T category
3, 4 vs 1,2 1.844 0.997-3.413 0.051
Lymph node metastasis
Positive vs negative 1.79 1.106-2.736 0.017 1.718 1.092-2.702 0.019
Tumor location
proximal vs distal 1.108 0.671-1.736 0.752
Lymphatic invasion
Positive vs negative 1.332 0.855-2.075 0.205
Arterial invasion
Positive vs negative 1.209 0.554-2.637 0.634
Venous invasion
Positive vs negative 1.579 0.812-3.071 0.178
Intrapancreatic nerve invasion
Positive vs negative 1.452 0.930-2.267 0.101
Tumor differentiation
grade 1,2 vs grade 3,4 1.452 0.826-2.551 0.195
Tumor stromal volume
med/int vs scir 0.724 0.453-1.156 0.176
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tumor aggressiveness in PDAC, as has been previously
reported [25,26].
IGF bioavailability is regulated by a family of six IGF-
binding proteins (IGFBP), of which IGFBP3 is the major
IGF carrier protein [17]. The function of IGFBP3 is con-
troversial. IGFBP3 has been shown to produce either in-
hibition [27-29] or potentiation [30-32] of IGF effects. The
direction of the effect may depend on the cell type [27]. In
this study, favorable survival in the IGFBP3-positive group
was noted, but statistical significance was not obtained
(Figure 2). IGFBP3 expression had an inverse association
with venous invasion. These findings suggest that IGFBP3
might show antiproliferative effects in PDAC. IGFBP3 ex-
pression had a significant association with proximal tu-
mors. Most insulin is secreted from the distal pancreas.IGFBP3 expression might be associated with lesions
involving insulin secretion.
Next, the significance of the combination of IGF1R ex-
pression and IGFBP3 expression was evaluated. Tumors
with IGF1R-positive and IGFBP3-negative expression were
significantly frequently found at an advanced clinical stage
(II or III), compared to the other groups. The prognosis of
patients with IGF1R-positive and IGFBP3-negative PDAC
was poorer than that of other groups, especially in patients
with stage II tumors (Figure 3). The IGF1R-positive and
IGFBP3-negative subgroup was the group with the
worst prognosis (Figures 2 & 3). These findings suggest
that IGFBP3 could produce inhibition of IGF effects.
Decreased IGFBP3 production and increased IGF1R ex-
pression in pancreas tumors might enhance the tumori-
genesis and cell motility as previously reported [26,33,34].
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important to determine the adjuvant therapy. This is espe-
cially true in patients with stage II tumors, because the
local recurrence rate of PDAC is high, even in patients
with curative R0 operations. The present study suggests
that combined evaluation of IGF1R expression and
IGFBP3 expression is a useful prognostic factor in pancre-
atic cancer, especially with clinical stage II tumors.
Although IGFBP3 is the major IGF carrier protein,
some paper reported that IGFBP3 has IGF-independent
antiproliferative and proapoptotic effects [20,21]. The
inhibition of IGF1-induced functions by cell surface-
associated IGFBP3 have been reported [27,29]; however,
the relationship between membrane-associated IGFBPs
and IGF1R signaling is less well understood. Therefor
significance of co-expression of IGFBP3 and IGF1R in
PDAC remains obscure. We then analyzed the signifi-
cance of IGF1R-negative and IGFBP3-positive group
with respect to overall survival (in the right bottom dia-
gram of Figures 2 & 3), which might clarify whether
IGFBP3 is IGF1/IGF1R signaling-independent or not.
Although IGFBP3 expression alone tended to be associ-
ated with overall survival (p = 0.079), co-expression of
IGF1R-negative and IGFBP3-positive PDAC was not
associated with overall survival (p = 0.218). These data
suggested that the function of IGFBP3 might be
dependent on IGF1R expression.
Conclusion
IGF1R signaling might be associated with tumor aggres-
siveness, and IGFBP3 might show antiproliferative effects
in pancreatic cancer. Both high IGF1R expression and low
IGFBP3 expression represent useful prognostic markers
for patients with curatively resected pancreatic cancer.
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